A recent multicenter retrospective study published in 2024 further validated tirzepatides real-world efficacy in OSAS management
For a medication that affects metabolic function, blood sugar regulation, and gastrointestinal health, some medical professionals argue that baseline blood work should be standard
It's not a "lose weight fast" product
These drugs copy a hormone which boosts insulin release, decreases glucagon, and slows the gastric emptying process
Others notice nausea, fullness, or food aversions first
Projected revenue for each product from 2025 through 2030, based on consensus estimates from Wall Street analysts, are used to calculate the forecasted cumulative revenue to the end of the decade